Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 5/20 | 0.33 |
| ▸ | IRAK1 | P51617 | 11/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 11/20 | 0.33 |
| ▸ | MPO | P05164 | 1/20 | 0.33 |
| ▸ | HSD17B13 | Q7Z5P4 | 1/20 | 0.33 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.32 |
| ▸ | HPGDS | O60760 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2364847 | 0.89 | IRAK1 (0.41) | METIRAK1IRAK4 | |
| SCHEMBL2276244 | 0.88 | MET (0.40) | METIRAK1IRAK4 | |
| SCHEMBL2222577 | 0.87 | IGF1R (0.37) | MET | |
| SCHEMBL12516405 | 0.86 | MET (0.40) | METIRAK1IRAK4HSD17B13ENPP2 | |
| SCHEMBL2224345 | 0.85 | MET (0.37) | METIRAK1IRAK4HSD17B13ENPP2 | |
| SCHEMBL13274582 | 0.85 | MET (0.37) | METIRAK1IRAK4HSD17B13ENPP2 | |
| SCHEMBL255611 | 0.85 | MET (0.41) | METHSD17B13ENPP2 | |
| SCHEMBL2222464 | 0.85 | MPO (0.35) | METIRAK1IRAK4MPOHSD17B13 | |
| SCHEMBL2221300 | 0.85 | HSD17B13 (0.38) | METIRAK1IRAK4HSD17B13ENPP2 | |
| SCHEMBL2222601 | 0.85 | HSD17B13 (0.36) | METIRAK1IRAK4MPOHSD17B13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120264735-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2012-10-18 | — | — | US | claimed |
| EP-2515657-A1 | TYROSINE KINASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2012-10-31 | — | — | EP | disclosed |
| US-20120264735-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2012-10-18 | — | — | US | disclosed |
| US-20120264735-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2012-10-18 | — | — | US | disclosed |
| US-20120264735-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2012-10-18 | — | — | US | disclosed |
| WO-2011084402-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2011-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264735-A1 | TYROSINE KINASE INHIBITORS | ABL1, MET, ERBB2 | MET 2/4885IRAK1 584/4885IRAK4 629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.